标题
The Aurora kinase inhibitors in cancer research and therapy
作者
关键词
Aurora kinases, Protein kinases, Small-molecule inhibitors, Cancer, Cell cycle
出版物
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume 142, Issue 9, Pages 1995-2012
出版商
Springer Nature
发表日期
2016-03-01
DOI
10.1007/s00432-016-2136-1
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- The potential role of Akt phosphorylation in human cancers
- (2017) J. Cicenas INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS
- A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma
- (2015) Graham P. Collins et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors
- (2015) Manik Amin et al. INVESTIGATIONAL NEW DRUGS
- Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108
- (2015) Paul M. Barr et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of N-(4-(3-(2-Aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), A Highly Selective, Orally Bioavailable Inhibitor of Aurora Kinases with Activity against Multidrug-Resistant Cancer Cell Lines
- (2015) Stephanie Geuns-Meyer et al. JOURNAL OF MEDICINAL CHEMISTRY
- Kinase inhibitors and monoclonal antibodies in oncology: clinical implications
- (2015) Helen Gharwan et al. Nature Reviews Clinical Oncology
- Combined treatment with ABT-737 and VX-680 induces apoptosis in Bcl-2- and c-FLIP-overexpressing breast carcinoma cells
- (2015) JUNG EUN CHOI et al. ONCOLOGY REPORTS
- The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells
- (2015) Shu-Feng Zhou et al. Drug Design Development and Therapy
- Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway
- (2015) Shu-Feng Zhou et al. Drug Design Development and Therapy
- Aurora kinase A controls meiosis I progression in mouse oocytes
- (2014) Adela Saskova et al. CELL CYCLE
- Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study
- (2014) Gerald Falchook et al. INVESTIGATIONAL NEW DRUGS
- Anticancer activity of the Aurora A kinase inhibitor MK-5108 in non-small-cell lung cancer (NSCLC) in vitro as monotherapy and in combination with chemotherapies
- (2014) Danielle C. Chinn et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposure-safety relationships
- (2014) Karthik Venkatakrishnan et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Inhibition of Aurora B by CCT137690 sensitizes colorectal cells to radiotherapy
- (2014) Xiaoyu Wu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Alisertib (MLN8237), a selective Aurora-A kinase inhibitor, induces apoptosis in human tongue squamous cell carcinoma cell both in vitro and in vivo
- (2014) Lin Qi et al. TUMOR BIOLOGY
- AZD1152-HQPA induces growth arrest and apoptosis in androgen-dependent prostate cancer cell line (LNCaP) via producing aneugenic micronuclei and polyploidy
- (2014) Ali Zekri et al. TUMOR BIOLOGY
- Primary effusion lymphoma in an elderly patient effectively treated by lenalidomide: case report and review of literature
- (2014) A Antar et al. Blood Cancer Journal
- Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer
- (2014) Channing J. Paller et al. Cancer Medicine
- Highlights of the Latest Advances in Research on CDK Inhibitors
- (2014) Jonas Cicenas et al. Cancers
- Aurora kinase inhibitor AZD1152 has an additional effect of platinum on a sequential application at the human ovarian cancer cell line SKOV3
- (2013) Yaxi Ma et al. ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- Androgen receptor phosphorylation at serine 515 by Cdk1 predicts biochemical relapse in prostate cancer patients
- (2013) J M Willder et al. BRITISH JOURNAL OF CANCER
- The Investigational Aurora Kinase A Inhibitor MLN8237 Induces Defects in Cell Viability and Cell-Cycle Progression in Malignant Bladder Cancer Cells In Vitro and In Vivo
- (2013) N. Zhou et al. CLINICAL CANCER RESEARCH
- Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML
- (2013) Hagop M. Kantarjian et al. Clinical Lymphoma Myeloma & Leukemia
- Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia
- (2013) Kevin R. Kelly et al. INVESTIGATIONAL NEW DRUGS
- The Aurora Kinases Inhibitor VE-465 is a Novel Treatment for Glioblastoma Multiforme
- (2013) Pei-Ying Lee et al. ONCOLOGY
- Spindle assembly checkpoint gene expression in childhood adrenocortical tumors (ACT): Overexpression of Aurora kinases A and B is associated with a poor prognosis
- (2013) Kleiton Silva Borges et al. PEDIATRIC BLOOD & CANCER
- Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3
- (2012) Siqing Fu et al. CANCER BIOLOGY & THERAPY
- Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia
- (2012) Mike Dennis et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A functional cooperativity between Aurora A kinase and LIM kinase1
- (2012) Lisa Ritchey et al. CELL CYCLE
- Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study
- (2012) Y. P. Mosse et al. CLINICAL CANCER RESEARCH
- Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
- (2012) A. Cervantes et al. CLINICAL CANCER RESEARCH
- Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors
- (2012) Gary K. Schwartz et al. INVESTIGATIONAL NEW DRUGS
- Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines
- (2012) Jodi A. Muscal et al. INVESTIGATIONAL NEW DRUGS
- Furry Protein Promotes Aurora A-mediated Polo-like Kinase 1 Activation
- (2012) Masanori Ikeda et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Nucleophosmin/B23 activates Aurora A at the centrosome through phosphorylation of serine 89
- (2012) David Reboutier et al. JOURNAL OF CELL BIOLOGY
- Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns
- (2012) A S Moore et al. LEUKEMIA
- MK-0457, an Aurora kinase and BCR–ABL inhibitor, is active in patients with BCR–ABL T315I leukemia
- (2012) F J Giles et al. LEUKEMIA
- Imatinib Mesylate (Gleevec©): Targeted Therapy Against Cancer with Immune Properties
- (2012) Moustapha Zoubir et al. Endocrine Metabolic & Immune Disorders-Drug Targets
- Aurora-C interacts with and phosphorylates the transforming acidic coiled-coil 1 protein
- (2011) Jean-Charles Gabillard et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Effects of AZD1152, a selective Aurora B kinase inhibitor, on Burkitt's and Hodgkin's lymphomas
- (2011) Naoki Mori et al. BIOCHEMICAL PHARMACOLOGY
- Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma
- (2011) Wenqing Qi et al. BIOCHEMICAL PHARMACOLOGY
- Vincristine potentiates the anti-proliferative effect of an aurora kinase inhibitor, VE-465, in myeloid leukemia cells
- (2011) Kozue Yoshida et al. BIOCHEMICAL PHARMACOLOGY
- Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia
- (2011) B. Lowenberg et al. BLOOD
- Aurora-C kinase supports mitotic progression in the absence of Aurora-B
- (2011) Scott D. Slattery et al. CELL CYCLE
- Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays
- (2011) M. G. Manfredi et al. CLINICAL CANCER RESEARCH
- Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours
- (2011) Patrick Schöffski et al. EUROPEAN JOURNAL OF CANCER
- MLN8054, A Small Molecule Inhibitor of Aurora Kinase A, Sensitizes Androgen-Resistant Prostate Cancer to Radiation
- (2011) Luigi Moretti et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)
- (2011) Ron J. Keizer et al. INVESTIGATIONAL NEW DRUGS
- The CDK inhibitors in cancer research and therapy
- (2011) Jonas Cicenas et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells
- (2011) Kleiton Silva Borges et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Phosphorylation at serine 331 is required for Aurora B activation
- (2011) Eleni Petsalaki et al. JOURNAL OF CELL BIOLOGY
- High Chromosome Number in hematological cancer cell lines is a Negative Predictor of Response to the inhibition of Aurora B and C by GSK1070916
- (2011) Christopher Moy et al. Journal of Translational Medicine
- A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia
- (2011) Kosuke Tsuboi et al. LEUKEMIA RESEARCH
- The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN-Amplified Neuroblastoma In Vivo
- (2011) A. Faisal et al. MOLECULAR CANCER THERAPEUTICS
- Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death
- (2011) V Ratushny et al. ONCOGENE
- Enhanced Radiosensitivity of Androgen-Resistant Prostate Cancer: AZD1152-Mediated Aurora Kinase B Inhibition
- (2011) Kenneth J Niermann et al. RADIATION RESEARCH
- Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors
- (2010) D. S. Boss et al. ANNALS OF ONCOLOGY
- 3-Cyano-6-(5-methyl-3-pyrazoloamino)pyridines: Selective Aurora A kinase inhibitors
- (2010) Ryoichi Ando et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma
- (2010) G. Gorgun et al. BLOOD
- Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors
- (2010) E. Claire Dees et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors
- (2010) Anne M. Traynor et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase
- (2010) A. Chakravarty et al. CANCER RESEARCH
- Preclinical Evaluation of AMG 900, a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines
- (2010) M. Payton et al. CANCER RESEARCH
- Aurora-C and Aurora-B share phosphorylation and regulation of cenp-A and borealin during mitosis
- (2010) Scott D. Slattery et al. CELL CYCLE
- Arpc1b, a centrosomal protein, is both an activator and substrate of Aurora A
- (2010) Poonam R. Molli et al. JOURNAL OF CELL BIOLOGY
- The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib
- (2010) Kevin R. Kelly et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Imidazo[4,5-b]pyridine Derivatives As Inhibitors of Aurora Kinases: Lead Optimization Studies toward the Identification of an Orally Bioavailable Preclinical Development Candidate
- (2010) Vassilios Bavetsias et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of GSK1070916, a Potent and Selective Inhibitor of Aurora B/C Kinase
- (2010) Nicholas D. Adams et al. JOURNAL OF MEDICINAL CHEMISTRY
- ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the chemosensitivity to cisplatin
- (2010) Liya Zhang et al. JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
- Aurora-C Kinase Deficiency Causes Cytokinesis Failure in Meiosis I and Production of Large Polyploid Oocytes in Mice
- (2010) Kuo-Tai Yang et al. MOLECULAR BIOLOGY OF THE CELL
- The FLT3 Internal Tandem Duplication Mutation Is a Secondary Target of the Aurora B Kinase Inhibitor AZD1152-HQPA in Acute Myelogenous Leukemia Cells
- (2010) M. Grundy et al. MOLECULAR CANCER THERAPEUTICS
- Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)
- (2010) John M. Maris et al. PEDIATRIC BLOOD & CANCER
- Increased Level of Phosphorylated ShcA Measured by Chemiluminescence-Linked Immunoassay Is a Predictor of Good Prognosis in Primary Breast Cancer Expressing Low Levels of Estrogen Receptor
- (2010) Jonas Cicenas et al. Cancers
- Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1
- (2009) Kelly Anderson et al. BIOCHEMICAL JOURNAL
- In vitroanti-myeloma activity of the Aurora kinase inhibitor VE-465
- (2009) Joseph M. Negri et al. BRITISH JOURNAL OF HAEMATOLOGY
- SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo
- (2009) Jennifer P. Arbitrario et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Plk1 and Aurora A regulate the depolymerase activity and the cellular localization of Kif2a
- (2009) C.-Y. Jang et al. JOURNAL OF CELL SCIENCE
- The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma
- (2009) Arihiro Aihara et al. JOURNAL OF HEPATOLOGY
- GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models
- (2009) M. A. Hardwicke et al. MOLECULAR CANCER THERAPEUTICS
- The cell cycle as a therapeutic target againstTrypanosoma brucei: Hesperadin inhibits Aurora kinase-1 and blocks mitotic progression in bloodstream forms
- (2009) Neal Jetton et al. MOLECULAR MICROBIOLOGY
- Aurora kinase B modulates chromosome alignment in mouse oocytes
- (2009) Kristy Shuda et al. MOLECULAR REPRODUCTION AND DEVELOPMENT
- An essential role of the aPKC–Aurora A–NDEL1 pathway in neurite elongation by modulation of microtubule dynamics
- (2009) Daisuke Mori et al. NATURE CELL BIOLOGY
- Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
- (2009) Pasi A. Jänne et al. NATURE REVIEWS DRUG DISCOVERY
- ZM447439, a Novel Promising Aurora Kinase Inhibitor, Provokes Antiproliferative and Proapoptotic Effects Alone and in Combination with Bio- and Chemotherapeutic Agents in Gastroenteropancreatic Neuroendocrine Tumor Cell Lines
- (2009) I. Georgieva et al. NEUROENDOCRINOLOGY
- Discovery of a potent and selective Aurora kinase inhibitor
- (2008) Johan D. Oslob et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate
- (2008) Y. Dai et al. BLOOD
- The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma
- (2008) Robert P. Evans et al. BRITISH JOURNAL OF HAEMATOLOGY
- Aurora Kinase A Inhibition Leads to p73-Dependent Apoptosis in p53-Deficient Cancer Cells
- (2008) Altaf A. Dar et al. CANCER RESEARCH
- Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL:In vitroandin vivostudies
- (2008) Daigo Akahane et al. CANCER SCIENCE
- Targeting Aurora Kinase with MK-0457 Inhibits Ovarian Cancer Growth
- (2008) Y. G. Lin et al. CLINICAL CANCER RESEARCH
- Cotreatment with Vorinostat Enhances Activity of MK-0457 (VX-680) against Acute and Chronic Myelogenous Leukemia Cells
- (2008) W. Fiskus et al. CLINICAL CANCER RESEARCH
- Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines
- (2008) Y. Arlot-Bonnemains et al. ENDOCRINE-RELATED CANCER
- Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts
- (2008) E. Walsby et al. HAEMATOLOGICA
- The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma
- (2008) Zhong-Zhe Lin et al. JOURNAL OF HEPATOLOGY
- Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery
- (2008) Libor Macůrek et al. NATURE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started